{
    "info": {
        "nct_id": "NCT05969496",
        "official_title": "Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX)",
        "inclusion_criteria": "* Provision to sign and date the consent form.\n* Stated willingness to comply with all study procedures and be available for the duration of the study.\n* Participant self-identified gender ages >/= 18 years old is acceptable and appropriate if they meet other inclusion criteria.\n* Histologically proven clear cell component RCC.\n* An upfront candidate for definitive surgery per treating Urologist.\n* Suitable for and willing to undergo nephrectomy (either cytoreductive or with curative intent) per treating urologist.\n* T Stage of any of the following: cT3b, cT3c, cT4\n* N stage of any of the following: cN0 or cN1\n* M stage of any of the following: cM0 or cM1\n* ECOG performance status 0 - 2.\n* Urinalysis <2+ protein. If dipstick is ≥2+ then a 24-hour urine collection should be performed, and the patient may enter the trial if urinary protein is <2g per 24 hours.\n* All participants who have reproductive potential must have a negative serum or urine pregnancy test within a maximum of 14 days prior to starting trial treatment.\n\nReproductive potential is defined as the following:\n\n* Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n  * Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)\n  * Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy\n  * For males with reproductive potential, use effective birth control during treatment with Axitinib and Pembrolizumab is recommended.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to enrollment.\n* Has had major surgery within 4 weeks or received radiation therapy within 1 week prior to enrollment to the study.\n* Has had prior treatment with any anti-programmed cell death (anti-PD-1) or programmed cell death ligand 1 (PD-L1), or an antibody targeting any other immune-regulatory receptors or mechanisms.\n* Has received prior systemic anti-cancer therapy for RCC with vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR).\n* Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema, hypotension, bronchospasm, angioedema, or anaphylaxis) to Axitinib.\n* Has a diagnosis of immunodeficiency OR is receiving a systemic steroid therapy greater than Prednisone 10 mg daily or a steroid equivalent, or any other form of immunosuppressive therapy within 7 days prior to enrollment to the study except in the case of central nervous system (CNS) metastases.\n* Has an active autoimmune disease requiring systemic treatment within the past 2 years OR a documented history of clinically severe autoimmune disease. Note: Participants with vitiligo, Sjogren's syndrome, Type 1 diabetes, resolved childhood asthma/atopy, hypothyroidism or adrenal or pituitary insufficiency who are stable on hormone replacement are not excluded.\n* Has a known additional malignancy that has progressed or has required active treatment in the last 3 years. Note: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ such as breast cancer in situ, thyroid cancer (papillary, hurthle cell or follicular), or localized prostate cancer are acceptable if they have undergone potentially curative therapy.\n* Has known active CNS metastases and/or carcinomatous meningitis.\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n* ALT or AST above 3 times the upper limit of normal\n* Has received a live virus vaccine within 30 days of enrollment to the study.\n* Active GI bleeding, as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy.\n* Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease, ulcerative colitis or other GI condition associated with increased risk of perforation.\n* Has QT interval corrected for heart rate (QTc) ≥480 msec.\n* Has a history of any of the following cardiovascular conditions within 12 months of enrollment to the study:\n\n  * Myocardial infarction\n  * Unstable angina pectoris\n  * Cardiac angioplasty or stenting\n  * Coronary/peripheral artery bypass graft\n  * Class III or IV congestive heart failure per New York Heart Association\n  * Cerebrovascular accident or transient ischemic attack\n* Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg on 3 or more dose optimized anti- hypertensive medication.\n* Has evidence of inadequate wound healing per treating physician discretion.\n* Has active bleeding disorder or other history of significant bleeding episodes within 30 days of enrollment to the study.\n* Has current use (within 7 days of enrollment) or anticipated need for treatment with drugs or foods that are known to be strong cytochrome P450 (CYP3A4/5) inhibitors.\n* Has current use (within 7 days of enrollment) or anticipated need for treatment with drugs that are known strong CYP3A4/5 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort; or drugs that are known with proarrhythmic potential.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study by subject self-report.\n* Has had a prior solid organ transplant.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* M stage of any of the following: cM0 or cM1",
            "criterions": [
                {
                    "exact_snippets": "M stage of any of the following: cM0 or cM1",
                    "criterion": "M stage",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "cM0",
                                "cM1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provision to sign and date the consent form.",
            "criterions": [
                {
                    "exact_snippets": "Provision to sign and date the consent form",
                    "criterion": "consent form",
                    "requirements": [
                        {
                            "requirement_type": "provision to sign and date",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant self-identified gender ages >/= 18 years old is acceptable and appropriate if they meet other inclusion criteria.",
            "criterions": [
                {
                    "exact_snippets": "Participant self-identified gender ... is acceptable and appropriate",
                    "criterion": "self-identified gender",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ages >/= 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urinalysis <2+ protein. If dipstick is ≥2+ then a 24-hour urine collection should be performed, and the patient may enter the trial if urinary protein is <2g per 24 hours.",
            "criterions": [
                {
                    "exact_snippets": "Urinalysis <2+ protein",
                    "criterion": "urine protein (dipstick)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "+"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If dipstick is ≥2+ then a 24-hour urine collection should be performed, and the patient may enter the trial if urinary protein is <2g per 24 hours",
                    "criterion": "urinary protein (24-hour collection)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "g per 24 hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy",
            "criterions": [
                {
                    "exact_snippets": "Women ≥50 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments",
                    "criterion": "amenorrhea duration after cessation of exogenous hormonal treatments",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation-induced menopause with last menses >1 year ago",
                    "criterion": "time since last menses after radiation-induced menopause",
                    "requirements": [
                        {
                            "requirement_type": "time since last menses",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy-induced menopause with last menses >1 year ago",
                    "criterion": "time since last menses after chemotherapy-induced menopause",
                    "requirements": [
                        {
                            "requirement_type": "time since last menses",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy",
                    "criterion": "surgical sterilization",
                    "requirements": [
                        {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "bilateral oophorectomy",
                                "bilateral salpingectomy",
                                "hysterectomy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Reproductive potential is defined as the following:",
            "criterions": [
                {
                    "exact_snippets": "Reproductive potential is defined as the following:",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "as the following"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For males with reproductive potential, use effective birth control during treatment with Axitinib and Pembrolizumab is recommended.",
            "criterions": [
                {
                    "exact_snippets": "males with reproductive potential",
                    "criterion": "male reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "use effective birth control during treatment with Axitinib and Pembrolizumab is recommended",
                    "criterion": "use of effective birth control",
                    "requirements": [
                        {
                            "requirement_type": "use during treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment agents",
                            "expected_value": [
                                "Axitinib",
                                "Pembrolizumab"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:",
            "criterions": [
                {
                    "exact_snippets": "Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.",
                    "criterion": "post-menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "amenorrhea_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "alternative_medical_cause",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically proven clear cell component RCC.",
            "criterions": [
                {
                    "exact_snippets": "Histologically proven clear cell component RCC",
                    "criterion": "renal cell carcinoma (RCC) with clear cell component",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "presence of clear cell component",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Suitable for and willing to undergo nephrectomy (either cytoreductive or with curative intent) per treating urologist.",
            "criterions": [
                {
                    "exact_snippets": "Suitable for ... nephrectomy (either cytoreductive or with curative intent) per treating urologist",
                    "criterion": "suitability for nephrectomy",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to undergo nephrectomy (either cytoreductive or with curative intent)",
                    "criterion": "willingness to undergo nephrectomy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy)",
            "criterions": [
                {
                    "exact_snippets": "Women <50 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "maximum age",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrheic for 12 months or more following cessation of exogenous hormonal treatments",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "following cessation of exogenous hormonal treatments"
                        }
                    ]
                },
                {
                    "exact_snippets": "luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution",
                    "criterion": "luteinizing hormone and follicle-stimulating hormone levels",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "post-menopausal range for the institution"
                        }
                    ]
                },
                {
                    "exact_snippets": "surgical sterilization (bilateral oophorectomy or hysterectomy)",
                    "criterion": "surgical sterilization",
                    "requirements": [
                        {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "bilateral oophorectomy",
                                "hysterectomy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status 0 - 2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0 - 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An upfront candidate for definitive surgery per treating Urologist.",
            "criterions": [
                {
                    "exact_snippets": "An upfront candidate for definitive surgery per treating Urologist",
                    "criterion": "candidate for definitive surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "upfront"
                        },
                        {
                            "requirement_type": "determination",
                            "expected_value": "per treating Urologist"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stated willingness to comply with all study procedures and be available for the duration of the study.",
            "criterions": [
                {
                    "exact_snippets": "Stated willingness to comply with all study procedures",
                    "criterion": "willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be available for the duration of the study",
                    "criterion": "availability for duration of study",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* T Stage of any of the following: cT3b, cT3c, cT4",
            "criterions": [
                {
                    "exact_snippets": "T Stage of any of the following: cT3b, cT3c, cT4",
                    "criterion": "T Stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "cT3b",
                                "cT3c",
                                "cT4"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* N stage of any of the following: cN0 or cN1",
            "criterions": [
                {
                    "exact_snippets": "N stage of any of the following: cN0 or cN1",
                    "criterion": "N stage",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "cN0",
                                "cN1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All participants who have reproductive potential must have a negative serum or urine pregnancy test within a maximum of 14 days prior to starting trial treatment.",
            "criterions": [
                {
                    "exact_snippets": "All participants who have reproductive potential",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum or urine pregnancy test",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "within a maximum of 14 days prior to starting trial treatment",
                    "criterion": "timing of pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "time before treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has a history of severe hypersensitivity reaction (e.g., generalized rash/erythema, hypotension, bronchospasm, angioedema, or anaphylaxis) to Axitinib.",
            "criterions": [
                {
                    "exact_snippets": "history of severe hypersensitivity reaction ... to Axitinib",
                    "criterion": "severe hypersensitivity reaction to Axitinib",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has QT interval corrected for heart rate (QTc) ≥480 msec.",
            "criterions": [
                {
                    "exact_snippets": "QT interval corrected for heart rate (QTc) ≥480 msec.",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intraluminal metastatic lesion with suspected bleeding, inflammatory bowel disease, ulcerative colitis or other GI condition associated with increased risk of perforation.",
            "criterions": [
                {
                    "exact_snippets": "Intraluminal metastatic lesion with suspected bleeding",
                    "criterion": "intraluminal metastatic lesion with suspected bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other GI condition associated with increased risk of perforation",
                    "criterion": "gastrointestinal condition associated with increased risk of perforation",
                    "requirements": [
                        {
                            "requirement_type": "risk of perforation",
                            "expected_value": "increased"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive ... within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug",
                    "criterion": "expectation to conceive",
                    "requirements": [
                        {
                            "requirement_type": "expectation during study period",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to ... father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug",
                    "criterion": "expectation to father children",
                    "requirements": [
                        {
                            "requirement_type": "expectation during study period",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has current use (within 7 days of enrollment) or anticipated need for treatment with drugs that are known strong CYP3A4/5 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort; or drugs that are known with proarrhythmic potential.",
            "criterions": [
                {
                    "exact_snippets": "current use (within 7 days of enrollment) or anticipated need for treatment with drugs that are known strong CYP3A4/5 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort",
                    "criterion": "use of strong CYP3A4/5 inducers",
                    "requirements": [
                        {
                            "requirement_type": "current use within 7 days or anticipated need",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current use (within 7 days of enrollment) or anticipated need for treatment with ... drugs that are known with proarrhythmic potential",
                    "criterion": "use of drugs with proarrhythmic potential",
                    "requirements": [
                        {
                            "requirement_type": "current use within 7 days or anticipated need",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known additional malignancy that has progressed or has required active treatment in the last 3 years. Note: Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ such as breast cancer in situ, thyroid cancer (papillary, hurthle cell or follicular), or localized prostate cancer are acceptable if they have undergone potentially curative therapy.",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy that has progressed or has required active treatment in the last 3 years.",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression or active treatment within last 3 years",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ such as breast cancer in situ, thyroid cancer (papillary, hurthle cell or follicular), or localized prostate cancer are acceptable if they have undergone potentially curative therapy.",
                    "criterion": "specific low-risk malignancies (basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ, localized prostate cancer)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "curative therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "history of (non-infectious) pneumonitis that required steroids",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had major surgery within 4 weeks or received radiation therapy within 1 week prior to enrollment to the study.",
            "criterions": [
                {
                    "exact_snippets": "Has had major surgery within 4 weeks ... prior to enrollment to the study",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received radiation therapy within 1 week prior to enrollment to the study",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating in ... a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "past participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has used an investigational device within 4 weeks prior to enrollment",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had a prior solid organ transplant.",
            "criterions": [
                {
                    "exact_snippets": "Has had a prior solid organ transplant",
                    "criterion": "prior solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has active bleeding disorder or other history of significant bleeding episodes within 30 days of enrollment to the study.",
            "criterions": [
                {
                    "exact_snippets": "Has active bleeding disorder",
                    "criterion": "bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other history of significant bleeding episodes within 30 days of enrollment to the study",
                    "criterion": "significant bleeding episodes",
                    "requirements": [
                        {
                            "requirement_type": "history_within_days",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known active CNS metastases and/or carcinomatous meningitis.",
            "criterions": [
                {
                    "exact_snippets": "Has known active CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active GI bleeding, as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy.",
            "criterions": [
                {
                    "exact_snippets": "Active GI bleeding, as evidenced by hematemesis, hematochezia, or melena in the past 3 months",
                    "criterion": "active gastrointestinal (GI) bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evidence",
                            "expected_value": [
                                "hematemesis",
                                "hematochezia",
                                "melena"
                            ]
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of resolution documented by endoscopy or colonoscopy",
                    "criterion": "resolution of GI bleeding documented by endoscopy or colonoscopy",
                    "requirements": [
                        {
                            "requirement_type": "evidence of resolution",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "documentation method",
                            "expected_value": [
                                "endoscopy",
                                "colonoscopy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unstable angina pectoris",
            "criterions": [
                {
                    "exact_snippets": "Unstable angina pectoris",
                    "criterion": "unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Coronary/peripheral artery bypass graft",
            "criterions": [
                {
                    "exact_snippets": "Coronary/peripheral artery bypass graft",
                    "criterion": "coronary artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Coronary/peripheral artery bypass graft",
                    "criterion": "peripheral artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ALT or AST above 3 times the upper limit of normal",
            "criterions": [
                {
                    "exact_snippets": "ALT ... above 3 times the upper limit of normal",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST above 3 times the upper limit of normal",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active autoimmune disease requiring systemic treatment within the past 2 years OR a documented history of clinically severe autoimmune disease. Note: Participants with vitiligo, Sjogren's syndrome, Type 1 diabetes, resolved childhood asthma/atopy, hypothyroidism or adrenal or pituitary insufficiency who are stable on hormone replacement are not excluded.",
            "criterions": [
                {
                    "exact_snippets": "Has an active autoimmune disease requiring systemic treatment within the past 2 years",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a documented history of clinically severe autoimmune disease",
                    "criterion": "clinically severe autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a diagnosis of immunodeficiency OR is receiving a systemic steroid therapy greater than Prednisone 10 mg daily or a steroid equivalent, or any other form of immunosuppressive therapy within 7 days prior to enrollment to the study except in the case of central nervous system (CNS) metastases.",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving a systemic steroid therapy greater than Prednisone 10 mg daily or a steroid equivalent",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg Prednisone equivalent daily"
                            }
                        },
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to enrollment",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "use within days prior to enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has evidence of inadequate wound healing per treating physician discretion.",
            "criterions": [
                {
                    "exact_snippets": "Has evidence of inadequate wound healing per treating physician discretion.",
                    "criterion": "wound healing",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "physician discretion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study by subject self-report.",
            "criterions": [
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "psychiatric disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "substance abuse disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that would interfere with cooperation with the requirements of the study",
                    "criterion": "interference with cooperation with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "effect",
                            "expected_value": "would interfere"
                        }
                    ]
                },
                {
                    "exact_snippets": "by subject self-report",
                    "criterion": "subject self-report",
                    "requirements": [
                        {
                            "requirement_type": "source",
                            "expected_value": "subject self-report"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live virus vaccine within 30 days of enrollment to the study.",
            "criterions": [
                {
                    "exact_snippets": "Has received a live virus vaccine within 30 days of enrollment to the study.",
                    "criterion": "live virus vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live virus"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac angioplasty or stenting",
            "criterions": [
                {
                    "exact_snippets": "Cardiac angioplasty or stenting",
                    "criterion": "cardiac angioplasty",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Cardiac angioplasty or stenting",
                    "criterion": "cardiac stenting",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has current use (within 7 days of enrollment) or anticipated need for treatment with drugs or foods that are known to be strong cytochrome P450 (CYP3A4/5) inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "current use (within 7 days of enrollment) ... drugs or foods that are known to be strong cytochrome P450 (CYP3A4/5) inhibitors",
                    "criterion": "use of strong CYP3A4/5 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipated need for treatment with drugs or foods that are known to be strong cytochrome P450 (CYP3A4/5) inhibitors",
                    "criterion": "anticipated need for strong CYP3A4/5 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "anticipated_need",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior systemic anti-cancer therapy for RCC with vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR).",
            "criterions": [
                {
                    "exact_snippets": "Has received prior systemic anti-cancer therapy for RCC",
                    "criterion": "prior systemic anti-cancer therapy for RCC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR)",
                    "criterion": "type of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "target",
                            "expected_value": [
                                "vascular endothelial growth factor (VEGF)",
                                "VEGF receptors (VEGFR)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg on 3 or more dose optimized anti- hypertensive medication.",
            "criterions": [
                {
                    "exact_snippets": "poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg on 3 or more dose optimized anti- hypertensive medication",
                    "criterion": "systolic blood pressure (SBP)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "mm Hg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg on 3 or more dose optimized anti- hypertensive medication",
                    "criterion": "diastolic blood pressure (DBP)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "mm Hg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on 3 or more dose optimized anti- hypertensive medication",
                    "criterion": "number of dose optimized anti-hypertensive medications",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "medications"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Class III or IV congestive heart failure per New York Heart Association",
            "criterions": [
                {
                    "exact_snippets": "Class III or IV congestive heart failure per New York Heart Association",
                    "criterion": "congestive heart failure (NYHA classification)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Class III",
                                "Class IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cerebrovascular accident or transient ischemic attack",
            "criterions": [
                {
                    "exact_snippets": "Cerebrovascular accident",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "transient ischemic attack",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of any of the following cardiovascular conditions within 12 months of enrollment to the study:",
            "criterions": [
                {
                    "exact_snippets": "history of any of the following cardiovascular conditions within 12 months of enrollment",
                    "criterion": "cardiovascular conditions",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had prior treatment with any anti-programmed cell death (anti-PD-1) or programmed cell death ligand 1 (PD-L1), or an antibody targeting any other immune-regulatory receptors or mechanisms.",
            "criterions": [
                {
                    "exact_snippets": "Has had prior treatment with any anti-programmed cell death (anti-PD-1) or programmed cell death ligand 1 (PD-L1), or an antibody targeting any other immune-regulatory receptors or mechanisms.",
                    "criterion": "prior treatment with immune checkpoint inhibitors or immune-regulatory antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug class",
                            "expected_value": [
                                "anti-PD-1",
                                "PD-L1",
                                "antibody targeting any other immune-regulatory receptors or mechanisms"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}